The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence
- 1 May 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 19 (3), 308-313
- https://doi.org/10.1097/01.bor.0000265447.48722.04
Abstract
(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis. (2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab. (3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.Keywords
This publication has 14 references indexed in Scilit:
- British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years)Rheumatology, 2006
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Rheumatoid Arthritis: An Overview of New and Emerging TherapiesThe Journal of Clinical Pharmacology, 2005
- Do We Need New Treatment That Goes beyond Tumor Necrosis Factor Blockers for Rheumatoid Arthritis?Annals of the New York Academy of Sciences, 2005
- New therapies for rheumatoid arthritisClinical and Experimental Immunology, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4IgNew England Journal of Medicine, 2003
- Management of Rheumatoid ArthritisDisease Management and Health Outcomes, 2003
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Rheumatoid arthritisThe Lancet, 2001